Outlook Therapeutics, Inc. (NASDAQ:OTLK) has a beta value of 0.06 and has seen 1,056,556 shares traded in the last trading session. The company, currently valued at $81.51 Million, closed the last trade at $0.64 per share which meant it gained $0.02 on the day or 3.3% during that session. The OTLK stock price is -181.09% off its 52-week high price of $1.799 and 22.03% above the 52-week low of $0.499. If we look at the company’s 10-day average daily trading volume, we find that it stood at 723.78 Million shares traded. The 3-month trading volume is 3.73 Million shares.
The consensus among analysts is that Outlook Therapeutics, Inc. (OTLK) is a Buy stock at the moment, with a recommendation rating of 1.6. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 5 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.08.
Outlook Therapeutics, Inc. (NASDAQ:OTLK) trade information
Sporting 3.3% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Wednesday, Sep 09 when the OTLK stock price touched $0.6699 or saw a rise of 4.33%. Year-to-date, Outlook Therapeutics, Inc. shares have moved 8.63%, while the 5-day performance has seen it change 0.14%. Over the past 30 days, the shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have changed -54.22%. Short interest in the company has seen 2.68 Million shares shorted with days to cover at 0.72.
Wall Street analysts have a consensus price target for the stock at $5.25, which means that the shares’ value could jump 720.31% from current levels. The projected low price target is $3.25 while the price target rests at a high of $8. In that case, then, we find that the current price level is +1150% off the targeted high while a plunge would see the stock lose 407.81% from current levels.
Outlook Therapeutics, Inc. (OTLK) estimates and forecasts
Figures show that Outlook Therapeutics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained +17.17% over the past 6 months, with this year growth rate of -59.68%, compared to 13.7% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 33.3% and 71.4% for the next quarter. Revenue growth from the last financial year stood is estimated to be -98.4%.
5 analysts offering their estimates for the company have set an average revenue estimate of $130Million for the current quarter. 2 have an estimated revenue figure of $320Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $5.85 Million and $440Million respectively for this quarter and the next, and analysts expect sales will grow by -97.8% for the current quarter and -27.3% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +22.8% over the past 5 years. Earnings growth for 2020 is a modest +79.7%.